CoChat

Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines

Open access
Hossain, Md, Wall, Katherine · 2016 · Vaccines

The DOI matches its Crossref record; 85 of the 88 references it cites were found in a registry or an index.

Abstract

Aberrantly glycosylated mucin 1 (MUC1) is a recognized tumor-specific antigen on epithelial cell tumors. A wide variety of MUC1 glycopeptide anti-cancer vaccines have been formulated by many research groups. Some researchers have used MUC1 alone as an immunogen whereas other groups used different antigenic carrier proteins such as bovine serum albumin or keyhole limpet hemocyanin for conjugation with MUC1 glycopeptide. A variety of adjuvants have been used with MUC1 glycopeptides to improve their immunogenicity. Fully synthetic multicomponent vaccines have been synthesized by incorporating different T helper cell epitopes and Toll-like receptor agonists. Some vaccine formulations utilized liposomes or nanoparticles as vaccine delivery systems. In this review, we discuss the immunological evaluation of different conjugate or synthetic MUC1 glycopeptide vaccines in different tumor or mouse models that have been published since 2012.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines4030025

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Difference between normal mucin 1 (MUC1) and tumor-associated MUC1.
Figure 1 Difference between normal mucin 1 (MUC1) and tumor-associated MUC1.CC BY · PubMed Central
Figure 2 Antibody-mediated antigen uptake mechanism. Anti-rhamnose antibody binding to rhamnose on the vaccine allows recognition by Fc receptor (FcR) on antigen presenting cells and enhanced uptake.
Figure 2 Antibody-mediated antigen uptake mechanism. Anti-rhamnose antibody binding to rhamnose on the vaccine allows recognition by Fc receptor (FcR) on antigen presenting cells and enhanced uptake.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 83

Metadata

Authors
Hossain, M., & Wall, K.
Affiliations
University of Toledo (US)
Corresponding author
Wall, Katherine
Venue
Vaccines
Publisher
MDPI AG
Published
2016-07-26
Volume
4
Issue
3
Pages
25
ISSN
2076-393X (ISSN-L)
OpenAlex
W2480252091
Cited by
74
References
88
Citations by year
2026: 4 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 12 · 2019: 8 · 2018: 11 · 2017: 7
FWCI
0.84
Type
journal article
Language
en
Open access
Locations
  • Vaccines (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (GM094734)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
Keywords
MUC1 glycopeptide, cancer vaccines, tumor-specific antigens, mucin glycosylation, antigen conjugation, bovine serum albumin, keyhole limpet hemocyanin, vaccine adjuvants, helper T cell epitopes, TLR agonists, liposomes, nanoparticles, vaccine delivery systems, immunogenicity, tumor models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. https://app.cochat.ai/papers/10.3390/vaccines4030025
The paper
Hossain, M., & Wall, K. (2016). Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines. https://doi.org/10.3390/vaccines4030025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.